Patents by Inventor Euh Lim Oh

Euh Lim Oh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HYPOTENSIVE PHARMACEUTICAL COMPOSITION COMPRISING TRIPLE ACTIVATOR HAVING ACTIVITY FOR ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS
    Publication number: 20240024426
    Abstract: A method for lowering blood pressure is disclosed. The method includes administering a pharmaceutical composition to a subject in need thereof, wherein the composition contains a pharmaceutically acceptable excipient; and a peptide having an amino acid sequence of any one of SEQ ID NOS: 1 to 102. The peptide is in a form of a long-acting conjugate.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 25, 2024
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Seungjae BAEK, Jaeduk CHOI, Wonjung SHIN, Jung Kuk KIM, Jong Suk LEE, Jae Hyuk CHOI, Euh Lim OH
  • NOVEL CONJUGATE OF IMMUNE-STIMULATING IL-2 ANALOG AND PREPARATION METHOD THEREOF
    Publication number: 20240009317
    Abstract: The present invention relates to a long-acting conjugate of an interleukin-2 analog with altered binding affinity for interleukin-2 receptors.
    Type: Application
    Filed: March 31, 2022
    Publication date: January 11, 2024
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Yong Ho HEO, Euh Lim OH, Da Hyeon PARK, Jin Young KIM, Jun Sub PARK, Yu Yon KIM, A Ram LEE, Sang Yun KIM
  • USE OF TRIGONAL AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS IN TREATMENT OF SEQUELAE FOLLOWING RESPIRATORY INFECTIOUS DISEASES
    Publication number: 20230390362
    Abstract: Provided is use of a trigonal agonist having activities to all of glucagon, GLP-1, and GIP receptors, and/or a conjugate thereof in the prevention or treatment of sequelae following respiratory infectious diseases.
    Type: Application
    Filed: October 18, 2021
    Publication date: December 7, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jong Suk LEE, Jung Kuk LEE, Seon Myeong LEE, Sang Hyun LEE, Jeong A KIM, Euh Lim OH, Chong Yoon LIM
  • NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF
    Publication number: 20230382974
    Abstract: Provided are a triple agonist having activities on all of glucagon, GLP-1, and GIP receptors, and use thereof.
    Type: Application
    Filed: December 24, 2021
    Publication date: November 30, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk KIM, Jong Suk LEE, Euh Lim OH
  • PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS
    Publication number: 20230381333
    Abstract: Provided is a pharmaceutical composition for preventing or treating vasculitis, including a glucagon/GLP-1/GIP triple agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conjugate thereof.
    Type: Application
    Filed: October 18, 2021
    Publication date: November 30, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Eun Jung KIM, Jae Hyuk CHOI, Jung Kuk KIM, Won Ki KIM, Euh Lim OH
  • PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES
    Publication number: 20230381281
    Abstract: Provided is a pharmaceutical composition for preventing or treating lupus-associated disease, including a glucagon/GLP-1/GIP triple agonist, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conjugate thereof.
    Type: Application
    Filed: October 18, 2021
    Publication date: November 30, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Eun Jung KIM, Jae Hyuk CHOl, Jung Kuk KIM, Jeong A KIM, Euh Lim OH
  • IMMUNOSTIMULATING IL-2 ANALOGS
    Publication number: 20230348550
    Abstract: Modifications to interleukin-2 alpha receptors are disclosed. Interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors are disclosed.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 2, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Sang Yun KIM, Yong Ho HEO, Jin Young KIM, Cho Rong PARK, Jun Sub PARK, Hyun Soo RYU
  • THERAPEUTIC USE OF COMBINATION COMPRISING TRIPLE AGONISTIC LONG-ACTING CONJUGATE OR TRIPLE AGONIST
    Publication number: 20230310630
    Abstract: New therapeutic uses of a triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor are disclosed. The triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor, may be for preventing or treating a liver disease.
    Type: Application
    Filed: July 16, 2021
    Publication date: October 5, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk KIM, Jong Suk LEE, Sang Hyun LEE, Euh Lim OH
  • Immunostimulating IL-2 analogs
    Patent number: 11746137
    Abstract: The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: September 5, 2023
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim Oh, Sang Yun Kim, Yong Ho Heo, Jin Young Kim, Cho Rong Park, Jun Sub Park, Hyun Soo Ryu
  • THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON/GLP-1/GIP RECEPTORS FOR LUNG DISEASE
    Publication number: 20230118307
    Abstract: New uses of a triple agonist are disclosed. A triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, or conjugates thereof exhibits an activity of preventing and/or treating lung diseases. A use of the triple agonist or a conjugate thereof as a preventive and/or therapeutic agent for lung disease, and compositions and methods for preventing and/or treating lung cancer employing the triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, and/or conjugates are disclosed.
    Type: Application
    Filed: November 20, 2020
    Publication date: April 20, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Seon Myeong LEE, Jong Suk LEE, Jung Kuk KIM, Sang Hyun LEE, Euh Lim OH, Hyo Sang JO, Eun Jin PARK, Chong Yoon LIM
  • NOVEL IMMUNOSTIMULATING IL-2 ANALOGS
    Publication number: 20230124171
    Abstract: The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.
    Type: Application
    Filed: March 31, 2021
    Publication date: April 20, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Sang Yun KIM, Yong Ho HEO, Jin Young KIM, Cho Rong PARK, Jun Sub PARK, Hyun Soo RYU
  • TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
    Publication number: 20220213164
    Abstract: A triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Euh Lim OH, Jong Suk LEE, Young Jin PARK, Chang Ki LIM, Sung Youb JUNG, Se Chang KWON
  • Triple glucagon/GLP-1/GIP receptor agonist
    Patent number: 11332508
    Abstract: A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 17, 2022
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • NOVEL IMMUNOSUPPRESSIVE INTERLEUKIN 2
    Publication number: 20220025007
    Abstract: The present invention relates to an interleukin-2 analogue, which has altered binding affinity for interleukin-2 alpha receptor and interleukin-2 beta receptor, compared to the wild type.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 27, 2022
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Hyo Ran LEE, Jin Young KIM, Yong Ho HEO
  • LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
    Publication number: 20210188937
    Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 24, 2021
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Jong Suk LEE, Young Jin PARK, Chang Ki LIM, Sung Youb JUNG, Se Chang KWON
  • Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
    Patent number: 10981967
    Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 20, 2021
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • LONG-ACTING SINGLE-CHAIN INSULIN ANALOG AND CONJUGATE THEREOF
    Publication number: 20200254108
    Abstract: The present invention relates to a long-acting single-chain insulin analog, a conjugate thereof, and uses of the same. In addition, the present invention relates to a method for preparing a long-acting single-chain insulin analog and a conjugate thereof.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Yong Ho HEO, Euh Lim OH
  • Insulin analogs and use thereof
    Patent number: 10647753
    Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 12, 2020
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jin Young Kim, Euh Lim Oh, Jong Soo Lee, Hyung Kyu Lim, In Young Choi, Se Chang Kwon
  • Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
    Patent number: 10400020
    Abstract: The present invention relates to a long-acting conjugate of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 3, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Triple glucagon/GLP-1/GIP receptor agonist
    Patent number: 10370426
    Abstract: The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 6, 2019
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon